Mostrando 10 resultados de: 31
Filtros aplicados
Publisher
Journal of Nanobiotechnology(3)
Nanomaterials(3)
Journal of Alzheimer's Disease(2)
Nanomedicine(2)
Pharmaceutics(2)
Área temáticas
Enfermedades(21)
Medicina y salud(12)
Fisiología humana(5)
Cirugía y especialidades médicas afines(2)
Fisiología y materias afines(2)
Origen
scopus(31)
Benzodiazepines and Related Drugs as a Risk Factor in Alzheimer's Disease Dementia
ArticleAbstract: Benzodiazepines (BZDs) and Z-drugs are compounds widely prescribed in medical practice due to theirPalabras claves:Alzheimer's disease, benzodiazepines, COGNITION, dementia, RISK FACTORSAutores:Antoni Camins, Auladell C., Bulló M., Busquets O., Cano A., Castro-Torres R.D., Ettcheto M., Folch J., García M.L., Manzine P.R., Olloquequi J., Sanchez-Lopez E., Zárate C.B.Fuentes:scopusBiodegradable nanoparticles for the treatment of epilepsy: From current advances to future challenges
ReviewAbstract: Epilepsy is the second most prevalent neurological disease worldwide. It is mainly characterized byPalabras claves:Epilepsy, lipid nanoparticles, Nanomedicine, nanotechnology, neurodegenerative diseases, Polymeric nanoparticlesAutores:Antoni Camins, Bonilla L., Cano A., Espina M., Esteruelas G., Ettcheto M., García M.L., Sanchez-Lopez E., Souto E.M.B.Fuentes:scopusA novel rhein-huprine hybrid ameliorates disease-modifying properties in preclinical mice model of Alzheimer’s disease exacerbated with high fat diet
ArticleAbstract: Background: Alzheimer’s disease (AD) is characterized by a polyetiological origin. Despite the globaPalabras claves:Alzheimer’s disease, BACE1, BDNF, cognitive decline, dendritic spines, high-fat diet, neuroinflammation, Rhein-huprine hybrid, Tau, TLR4Autores:Antoni Camins, Auladell C., Bulló M., Cano A., Espinosa-Jimenez T., Ettcheto M., Folch J., Muñoz-Torrero D., Olloquequi J., Parcerisas A., Pont C., Sanchez-Lopez E., Verdaguer E.Fuentes:scopusDevelopment and optimization of Riluzole-loaded biodegradable nanoparticles incorporated in a mucoadhesive in situ gel for the posterior eye segment
ArticleAbstract: Riluzole-loaded PLGA nanoparticles (RLZ-NPs) were developed to improve the biopharmaceutical profilePalabras claves:Gellan gum, glaucoma, In situ gelling gel, PLGA nanoparticles, riluzoleAutores:Antoni Camins, Cano A., Espina M., Esteruelas G., Ettcheto M., García-Torra V., Halbaut L., Luisa García M., Sanchez-Lopez E., Souto E.M.B.Fuentes:scopusDevelopment of Peptide Targeted PLGA-PEGylated Nanoparticles Loading Licochalcone-A for Ocular Inflammation
ArticleAbstract: Licochalcone-A is a natural compound with anti-inflammatory properties. However, it possesses low waPalabras claves:cell-penetrating peptides, Licochalcone-A, Nanoparticles, Ocular inflammation, PLGAAutores:Antoni Camins, Cano A., Espina M., Ettcheto M., Galindo R., García M.L., Gómara M.J., Haro I., Sanchez-Lopez E.Fuentes:scopusCurrent advances in the development of novel polymeric nanoparticles for the treatment of neurodegenerative diseases
ReviewAbstract: Effective intervention is essential to combat the coming epidemic of neurodegenerative (ND) diseasesPalabras claves:brain disorders, Brain targeting, CNS nanomedicine, neurodegenerative diseases, neurological diseases, Polymeric nanoparticlesAutores:Antoni Camins, Cano A., Espina M., Ettcheto M., Galindo R., García M.L., Lopez-Machado A.L., Sanchez-Lopez E., Souto E.M.B., Turowski P.Fuentes:scopusCurrent applications of nanoemulsions in cancer therapeutics
ReviewAbstract: Nanoemulsions are pharmaceutical formulations composed of particles within a nanometer range. They pPalabras claves:Cáncer, Multifunctional nanoemulsions, Targeted deliveryAutores:Antoni Camins, Cano A., Dias-Ferreira J., Espina M., Ettcheto M., García M.L., Guerra M., Lopez-Machado A.L., Sanchez-Lopez E., Souto E.M.B.Fuentes:scopusArticle dexibuprofen biodegradable nanoparticles: One step closer towards a better ocular interaction study
ArticleAbstract: Ocular inflammation is one of the most prevalent diseases in ophthalmology, which can affect variousPalabras claves:Dexibuprofen, Drug delivery system, Nanoparticles, PLGAAutores:Alsafi Z., Antoni Camins, Calpena A.C., Cano A., Espina M., Esteruelas G., Ettcheto M., García M.L., Muñoz M., Ortiz A., Prat J., Pujol M., Sanchez-Lopez E., Souto E.M.B.Fuentes:scopusEpigallocatechin-3-gallate PEGylated poly(lactic-co-glycolic) acid nanoparticles mitigate striatal pathology and motor deficits in 3-nitropropionic acid intoxicated mice
ArticleAbstract: Aim: To compare free and nanoparticle (NP)-encapsulated epigallocatechin-3-gallate (EGCG) for the trPalabras claves:3-nitropropionic acid, Epigallocatechin-3-gallate, Huntington's disease, neurodegenerative diseases, PLGA-PEG, Polymeric nanoparticlesAutores:Antoni Camins, Auladell C., Barenys M., Cano A., Espina M., Ettcheto M., Folch J., García M.L., Kühne B.A., Sanchez-Lopez E., Souto E.M.B., Turowski P.Fuentes:scopusEpigallocatechin-3-gallate loaded PEGylated-PLGA nanoparticles: A new anti-seizure strategy for temporal lobe epilepsy
ArticleAbstract: Temporal lobe epilepsy is the most common type of pharmacoresistant epilepsy in adults. EpigallocatePalabras claves:Epigallocatechin-3-gallate, Epilepsy, PLGA-PEG, Polymeric nanoparticlesAutores:Antoni Camins, Auladell C., Barenys M., Calpena A.C., Cano A., Espina M., Ettcheto M., Folch J., García M.L., Sanchez-Lopez E.Fuentes:scopus